You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
469 Combining a safe PI3Kd inhibitor with chemotherapy and anti-PD1 in immunotherapy-refractory NSCLC: a proof-of-concept study to allow clinical trial design

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 202314209
Dec 20235108
Jan 20243407
Feb 20243202
Mar 20243105
Apr 20241603
May 20242802
Jun 20241801
Jul 20241204
Aug 20241603
Sep 20242601
Oct 20241007
Nov 20241006
Dec 20241006
Jan 20251007
Feb 2025406
Mar 2025208
Apr 2025103
May 2025008
Jun 2025003
Total453099